Company Overview
NewcelX Ltd., a biopharmaceutical company, engages in developing transformative stem-cell-derived therapies for Diabetes. The company develops NCEL-101, a cellular therapy product based on enriched pancreatic islet-like clusters for the treatment of Type 1 diabetes and Type 2 insulin dependent diabetes; AstroRx, an off-the-shelf cryopreserved cell therapy product for the treatment of Amyotrophic Lateral Sclerosis and neurodegenerative indications; and Dual Orexin-Receptor Agonist (DOXA), a small molecules platform for the treatment of sleep disorders, Neurodegenerative/ neuroinflammation diseases, and Diabetes Associated Neurological Disorders. It also develops iTOL-102, NCEL-201, NCEL-301, and NCEL-007. NewcelX Ltd. was founded in 2008 and is headquartered in Kloten, Switzerland.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.06.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -86.57% |
| 6 Months: | +18.61% |
| 3 Months: | +0.31% |
| 1 Month: | -1.81% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.32 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 88.3% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NCEL NewcelX Ltd. PHARMA | 3.25 | -1.50 | $18.77M | 0.00% | -34.12% | -114.48% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | - |
| Operating Expenses | - | 6.25M | 3.02M | 1.80M | 2.47M |
| Operating Income | - | -6.25M | -3.02M | -1.80M | -2.47M |
| EBITDA | - | -5.87M | -2.47M | -1.74M | -2.24M |
| Interest Expense | - | 78.04K | 239.00K | 5.04M | 6.01M |
| Pretax Income | - | -6.49M | -3.33M | -7.20M | -8.30M |
| Tax Provision | -142.57K | -47.39K | -52.68K | -8.21K | - |
| Net Income | - | -6.45M | -3.33M | -7.20M | -8.30M |
| Diluted EPS | - | -2.59 | -1.13 | -2.43 | -2.16 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 3.54M | 2.20M | 903.00K | 11.45M |
| Current Assets | - | 2.10M | 1.53M | 780.00K | 3.18M |
| Cash & Equivalents | - | 1.81M | 1.09M | 650.00K | 2.20M |
| Inventory | - | - | - | - | - |
| Receivables | 219.48K | - | - | - | - |
| Total Liabilities | - | 3.45M | 3.35M | 8.90M | 4.20M |
| Current Liabilities | - | 2.99M | 3.35M | 8.90M | 4.20M |
| Long Term Debt | - | 0 | 834.00K | - | - |
| Total Debt | - | 2.02M | 2.62M | 2.67M | 355.00K |
| Total Equity | - | 92.51K | -1.15M | -8.00M | 7.25M |
| Shares Outstanding | - | 2.57M | 2.96M | 2.96M | 4.80M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -5.67M | -3.44M | -1.07M | -2.77M |
| Investing Cash Flow | - | -186.15K | 103.00K | -6.00K | 1.70M |
| Financing Cash Flow | - | 1.06M | 2.85M | 450.00K | 2.63M |
| Capital Expenditure | - | -181.61K | -6.00K | -6.00K | -8.00K |
| Free Cash Flow | - | -5.86M | -3.45M | -1.07M | -2.77M |
| Net Change in Cash | - | -4.80M | -492.00K | -622.00K | 1.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -6,968.7% | 290.1% | 90.0% | -114.5% |
| ROCE % | - | -1,125.8% | 263.7% | 22.5% | -34.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | HRT Financial LP | 0.19% | 11.20K | $35.28K |
| 2 | Jones Financial Companies, L.L.L.P. | 0.01% | 700 | $2.21K |
| 3 | Corecap Advisors, LLC | - | 3 | $9 |
| 4 | Caitong International Asset Management Co., Ltd | - | 9 | $28 |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NCEL
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTFA3bktRUDZjN2g4X1pTOGNQampXMVdUbFh6QkhVQmE1Z2dvOHNyb0wzSzVhNTEzLTd3OU9zV3Utb1VkZVhGVU5xT19WZk5PS2pO?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
$NCEL stock is up 14% today. Here's what we see in our data. - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxOc0x4cmNtSE9aZWZKNHNnV3czWE1Ma1lMOHFKZ2xvb29CLWhiZjVRa1U2MmExYXNvNUgyam1LeUFLRG5zanhjcUpydmN4WXBON1VMbTJRZlYycF9IRXdtVEJ2VDZ3dDE0VDdzZVdYUmNRZk01c2VWbTRZWVhVdFZrLTVIdXB2ZlQwUkl1NS…
NCEL - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1oaU1ld1RScWxJWHdWN3NkTTJxb3VKaUx1S3FyOFZ1Tkp5R1F0Z2JBSGhXMHNXRW1SZWt1bWxBZ2F3QTdnQnc?oc=5" target="_blank">NCEL</a> <font color="#6f6f6f">Finviz</font>…
Stem-cell islets plus immune drug: NewcelX, Eledon target Type 1 diabetes - Stock Titan
<a href="https://news.google.com/rss/articles/CBMirgFBVV95cUxOQjBMLUFRNUozQmIzQkJfaEhjVEVoYUNJY21RVS1HOEFuNUgySFFZWHNoTEkxTTZGQ3pQa1llcUgyX1prZklGZmg2Yl9HbnAwNFkwNEo2WEZsMGRlUzVzd09WWmdtTVpubDZKQlBrd2lyUU1sU3ZaaE1NTlJtM0JNOTg0Y203WXQzRVpqNz…
What is the current Price Target and Forecast for NewcelX Ltd. (NCEL) - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMieEFVX3lxTE1JQnhveWJlQmtyajdQcGoydGU5amRlOHdxVF9jcHNpUl9VSVVYVjNZUm1PWnk2cWlkWU56alNua09ORXEyUUhaVk5vWW5PdFVKY3dpeEo5OEE4QjJOME13dlJBaDNYcVpoQkpPZEhNYkk2YWZMREZaYw?oc=5" target="_blank">What …
NCEL Stock Price and Chart — NASDAQ:NCEL - tradingview.com
<a href="https://news.google.com/rss/articles/CBMiXEFVX3lxTFBSeTJ0dm1pV0RaczgxVUlVT0htTGhYNlhOaWJ0OGpmZkVCYW5NTzZaZ3hyM0xaMVlpMlpHcFktX0l3d3k3UXA4OE5lUDMzT3A0RG5WWEhQMFpIQkZp?oc=5" target="_blank">NCEL Stock Price and Chart — NASDAQ:NCEL</a…
NCEL — Frequently Asked Questions
What is the current share price of NewcelX Ltd. (NCEL)?
As of 2026-09-19 21:16 PDT, NewcelX Ltd. (NCEL) trades at $3.25 on NasdaqCM. Its 52-week range is $1.88 to $27.90.
What is the market capitalisation of NCEL?
NewcelX Ltd. (NCEL) has a market capitalisation of $18.77M on NasdaqCM.
What is the P/E ratio of NCEL?
NCEL trades at a trailing price-to-earnings (P/E) ratio of -1.50. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 2.09.
What is the return on equity (ROE) of NCEL?
NCEL has a return on equity (ROE) of -114.48%. Its return on capital employed (ROCE) is -34.12%.
Is NCEL a good stock to buy?
This page provides a data-driven analysis of NewcelX Ltd. (NCEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.